Egypt strengthens pharmaceutical research partnership with Takeda to boost healthcare innovation

EGYPT—Egypt is intensifying efforts to strengthen pharmaceutical research and innovation through closer cooperation with Takeda Pharmaceutical Company.

This partnership forms part of a broader strategy to enhance the country’s healthcare and drug development ecosystem.

The Egyptian Drug Authority (EDA) recently held high-level talks with a senior delegation from Takeda to expand collaboration in scientific research and improve patients’ access to innovative treatments in Egypt.

The meeting brought together Ali El Ghamrawy, Chairperson of the EDA, and a Takeda delegation led by Khaled Sary.

Advancing research and regulatory frameworks

Discussions focused on advancing existing partnership projects and exploring new areas of cooperation in line with Egypt’s national strategy to support the healthcare sector and develop the pharmaceutical system.

Participants reviewed initiatives and regulatory policies aimed at improving medicine availability in Egypt and facilitating access to advanced therapies, particularly in priority therapeutic areas.

Takeda representatives outlined the latest developments in the company’s clinical trial activities and scientific research efforts in the Egyptian market.

They emphasized the importance of continued coordination with the Authority to strengthen research capabilities and support Egypt’s scientific ecosystem.

The delegation received a briefing on the Authority’s future vision for strengthening intellectual property protection for pharmaceutical products.

This move will improve the investment climate, align Egypt with international regulatory standards, and stimulate further growth in the country’s pharmaceutical sector.

Positioning Egypt as a regional hub

El Ghamrawy stressed the Authority’s commitment to supporting research initiatives and expanding the clinical trials framework in Egypt.

He noted that such efforts are essential to positioning the country as a regional hub for pharmaceutical research and development.

The chairperson added that the Authority remains keen to collaborate with leading global companies to exchange expertise and foster drug innovation for the benefit of Egyptian patients.

Company commits to expansion

Takeda Pharmaceutical Company officials expressed appreciation for the constructive partnership with the Authority and praised its role in strengthening the national pharmaceutical landscape and research environment.

They reaffirmed the company’s intention to expand its operations in Egypt, particularly in research, development, and clinical trials, to accelerate pharmaceutical innovation and ensure broader access to advanced treatments.

Building strategic partnerships

The meeting represents part of the Egyptian Drug Authority’s ongoing efforts to engage with leading international pharmaceutical companies and promote strategic partnerships that support industry development.

These collaborations aim to drive sustainable growth in Egypt’s healthcare sector while ensuring Egyptian patients benefit from cutting-edge medical treatments and therapies developed through advanced research and clinical trials.